Study: Reishi Triterpenes Reduce Inflammation in Crohn’s DiseaseκB signaling pathway—a master regulator of inflammation.
Study Design
Researchers isolated triterpene compounds from Reishi and studied their effects on inflammatory markers in human tissue samples from Crohn’s disease patients. They specifically examined the NF-κB pathway, which controls the expression of many inflammatory genes.
Key Findings
Reishi triterpenes reduced inflammation by downregulating NF-κB signaling. This is significant because NF-κB is involved in many inflammatory conditions beyond Crohn’s disease, including arthritis, asthma, and various autoimmune disorders.
Why Extraction Method Matters
Triterpenes are fat-soluble compounds, meaning they require alcohol extraction to obtain. Water extraction alone would miss these anti-inflammatory compounds entirely. This finding supports the value of dual extraction methods for Reishi products—water for polysaccharides, alcohol for triterpenes.
Broader Implications
The NF-κB pathway is one of the most studied inflammatory pathways in medicine. Its involvement in Reishi’s anti-inflammatory effects provides a well-understood molecular mechanism that helps explain traditional uses of this mushroom.
Limitations to Consider
Crohn’s disease is a serious medical condition requiring professional management. This research is informative but does not suggest replacing medical treatment with mushroom supplements. Laboratory effects don’t always translate directly to clinical outcomes.
Citation
Liu, C., et al. (2015). Anti-inflammatory Effects of Ganoderma lucidum Triterpenoid in Human Crohn’s Disease Associated with Downregulation of NF-κB Signaling. BMC Complementary and Alternative Medicine, 15, 339.